Publications by authors named "Friedrich Kaiser"
Article Synopsis
- - A study was conducted to evaluate the safety and effectiveness of nirsevimab, a monoclonal antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV) in healthy infants during their first RSV season.
- - Infants aged 12 months or younger who were born at least 29 weeks gestation were randomly assigned to receive either nirsevimab or standard care, with results showing that 0.3% in the nirsevimab group were hospitalized compared to 1.5% in the standard-care group, indicating an 83.2% efficacy for nirsevimab.
- - The study also found that severe cases of RSV were less common in the nirsevimab
Background: Immunotherapy with the SQ-standardized grass tablet Grazax is efficacious and well-tolerated in adult patients with rhinoconjunctivitis. Allergic asthma and rhinoconjunctivitis are closely linked, and a strategy combining treatment of the upper and lower airways is recommended.
Objective: To investigate the efficacy of treatment with the grass tablet on grass pollen-induced rhinoconjunctivitis and asthma as well as the immunologic response and the safety profile in children.
The aim of the study was to confirm the safety of an orodispersible grass allergen tablet 75,000 SQ-T (Grazax, ALK-Abelló A/S, Hørsholm, Denmark) in children aged 5-12 yr. The study was randomized, double-blinded and placebo-controlled. Sixty children aged 5-12 yr suffering from grass pollen-induced rhinoconjunctivitis (with or without asthma) from five centres in two countries (three in Germany and two in Spain) participated in the study.
View Article and Find Full Text PDF